IGC IGC Pharma, Inc.
$0.28▼ -1.55%
Healthcare
Other
After hours
$0.28▲ +1.87%
Sep 11, 6:48 PM ET
Volume 412.5K
Avg Volume (10D) 862.5K
Key Metrics & Fundamentals
Market Cap
$28.80M
P/E Ratio
–
Div Yield
–%
52W Range
0.24 - 0.45
% vs 50 MA
0.14%
% vs 200 MA
-3.33%
RSI-14
44.2
MACD Histogram
+0.0000
Beta (1Y vs SPY)
0.98
Free Cash Flow
-$1.39M
Gross Rev
$317,000
Gross Profit
$55,000
EBITDA
-$2.40M
COGS
$262,000
Operating Exp
$2.51M
Operating Income
-$2.46M
EBIT
-$2.46M
Pretax Income
-$2.40M
Net Income
-$2.40M
EPS (Diluted)
-0.02
Price & Volume History
Loading chart…
Recent News
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure
ACCESS Newswire · Aug 17, 2026 12:30 PM
IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout
ACCESS Newswire · Aug 11, 2026 12:30 PM
IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign
ACCESS Newswire · Jul 29, 2026 12:30 PM
IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow
ACCESS Newswire · Jul 9, 2026 1:00 PM
IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company
ACCESS Newswire · Jul 7, 2026 1:00 PM
IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow
ACCESS Newswire · Jun 23, 2026 12:30 PM
Financial Overview - Income Statement
Quarterly
Mar 2026
See IGC's money flow as a full page
Social Sentiment
Avg +0.60 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.